CSL Parkville office)

Investor Relations

A Biotech Leader Driven by Our Promise

CSL is a global biotech leader. We conduct business in over 60 countries, with major facilities in Australia, Germany, Switzerland, the United Kingdom and the United States. With an unwavering focus on our promise to patients – to deliver life-saving and life-improving therapies that help many thousands of people live full lives – it is our dedicated management and employees that drive our performance.

  • US$45 billion

    market capitalization

  • US$6.9+ billion

    annual revenue

  • $1.3 billion

    2017 Net Profit After Tax

Shareholder information meeting
Shareholder Information
Group looking at their dividend information
Dividends

Contact Investor Relations

Mark Dehring

Head of Investor Relations
45 Poplar Road, Parkville
Victoria 3052
Australia
Phone: +61 3 9389 3407

Bernard Ronchi

Senior Manager, Investor Relations
45 Poplar Road, Parkville
Victoria 3052
Australia
Phone: +61 3 9389 3470

Product Pipeline

Delve into our portfolio of new products, improved products and manufacturing expertise.

Learn More
Innovation

Innovation spans across our organization with a focus on solving patients' unmet needs.

Learn More
Corporate Governance

Our Executive Board and management are committed to shareholder value.

Learn More

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

Thank you for subscribing
to the CSL newsletter